🟢 LLY is trading 3.16% up today after Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head trial

LLY is trading at $1041.44 (+3.16%) after its obesity drug Mounjaro outperformed Novo Nordisk's CagriSema in a head-to-head Phase 3 trial.

• The study demonstrated that tirzepatide achieved 25.5% weight loss versus 23% for CagriSema over an 84-week period.
• The results triggered a 15% drop in Novo Nordisk (NVO) shares while affirming Eli Lilly's leadership in the high-growth obesity treatment market.
• Novo Nordisk plans to evaluate a higher-dose version of CagriSema in a new study later this year to counter the findings.